COMMUNIQUÉS West-GlobeNewswire

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
26/03/2024
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and [...]
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
26/03/2024
David Pacitti is currently the President of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers; formerly Division Vice President of U.S. Commercial Operations, Sales, and Marketing at [...]
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
26/03/2024
BETHESDA, Md., March 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
26/03/2024
CUPERTINO, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research
26/03/2024
NEWPORT BEACH, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass [...]
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
26/03/2024
NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the [...]
GTG Global Collaborations and Innovation Update
26/03/2024
MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is [...]
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
26/03/2024
FOSTER CITY, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today [...]
Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
26/03/2024
OPGx-LCA5 will advance to the next highest dose in mid-2024 based on positive safety and efficacy data OPGx-LCA5 is well-tolerated and demonstrated clear signs of biological activity RESEARCH TRIANGLE PARK, N.C., March [...]
American Oncology Network Expands Footprint in Texas with the Addition of Woodlands Cancer Institute in Houston
26/03/2024
Woodlands Cancer Institute opens three clinic locations that provide medical oncology, radiation oncology and hematology care to its patients. WOODLANDS, Texas, March 26, 2024 (GLOBE NEWSWIRE) -- American Oncology [...]
HealthLynked Announces Exciting New Update with HealthLynked 3.2.0 - Transforming Patient-Care Through Innovation
26/03/2024
NAPLES, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. (OTCQB: HLYK), a pioneering healthcare network focused on enhancing the efficiency and quality of patient care, is thrilled to announce the [...]
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
26/03/2024
First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly selective and potentially best [...]
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
26/03/2024
In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with prior dose escalation [...]
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
26/03/2024
Data readout from Phase 3 clinical trial in the People's Republic of China ( “ PRC ”) evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical trial evaluating [...]
Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of team
26/03/2024
STEVENAGE, United Kingdom, March 26, 2024 (GLOBE NEWSWIRE) -- Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major [...]
Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2
26/03/2024
First in human phase I clinical study using OMV as an adjuvant for intranasal vaccination Avacc 10 ® intranasal booster vaccine induces a mucosal response and no adverse events Data will be presented at the World [...]
Annual General Meeting 2024: Tecan proposes election of an additional member of the Board of Directors and various amendments to the Articles of Incorporation
26/03/2024
Annual General Meeting 2024: Tecan proposes election of an additional member of the Board of Directors and various amendments to the Articles of Incorporation Monica Manotas proposed as a new member of the Board of [...]
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
26/03/2024
PRESS RELEASE REGULATED INFORMATION 26 March 2024, 07:00 a.m. CET Ghent, Belgium, 26 March 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of [...]
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
26/03/2024
VYVGART ® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory decision in Japan represents first global approval for VYVGART in ITP March 26, 2024 7:00 AM [...]

Pages